Team-Based Care Pathway Aims to Stop Muscle Loss in Nasopharyngeal Cancer Patients

Sarcopenia, the progressive loss of skeletal muscle mass and strength, has quietly become one of the most consequential complications of cancer treatment, and nowhere is the problem more acute than in nasopharyngeal carcinoma. Patients undergoing definitive treatment for this tumour, which typically combines induction chemotherapy with weeks of daily radiotherapy, face a barrage of treatment-related toxicities that strike directly at the ability to eat, swallow, and stay active. Dry mouth, nausea, taste alterations, mucositis, dysphagia, and fatigue converge to reduce dietary intake and physical activity, accelerating muscle loss precisely when the body needs reserves most. In a cohort of 394 patients with non-metastatic nasopharyngeal carcinoma, the prevalence of sarcopenia rose from 33.0 percent before treatment to 61.2 percent after chemoradiotherapy, a near-doubling over the course of care. The consequences are not merely cosmetic: sarcopenia has been linked to increased treatment toxicity, reduced response to chemotherapy, and poorer clinical outcomes overall.

What makes sarcopenia during cancer treatment so difficult to prevent is that it is not a single problem with a single fix. Its development reflects interacting nutritional, inflammatory, metabolic, immune, behavioural, and functional disturbances, all unfolding against the backdrop of a demanding treatment schedule. In nasopharyngeal carcinoma, toxicities affecting oral intake, swallowing, and salivary function during radiotherapy compound these processes, driving progressive deterioration in nutritional status, physical activity, and daily functioning. Because risk and supportive care needs shift across the treatment trajectory, a preventive strategy that works in week one may be inadequate by week six. Yet current approaches remain fragmented, often delivered as isolated interventions targeting one aspect of care at a time. Nutritional supplementation, the most common strategy, plays an essential role in maintaining energy and protein intake, but interventions focused on nutrition alone may be insufficient to address the complex and evolving factors contributing to muscle loss during definitive treatment.

A research team led by Lijuan Xia of the General Hospital of Ningxia Medical University in China, working with colleagues including Naoko Hayashi of St. Luke’s International University in Tokyo, has now tackled this gap head-on. Writing in the journal Supportive Care in Cancer, they report the development of a context-sensitive supportive care pathway designed to coordinate multidisciplinary sarcopenia prevention across the entire nasopharyngeal carcinoma treatment trajectory. Crucially, the study does not claim to prove that the pathway works. Instead, its contribution lies in providing a transparent, theoretically informed account of how such a pathway should be built, drawing together evidence, theory, stakeholder perspectives, and real-world constraints before any effectiveness testing begins. The work was guided by the updated Medical Research Council framework for developing and evaluating complex interventions, a methodological blueprint that emphasises integrating multiple sources of knowledge through iterative refinement.

The development process was anchored by a multidisciplinary team of thirteen healthcare professionals: four physicians, four nurses, two dietitians, one physiotherapist, one clinical pharmacist, and one psychologist, each with at least fifteen years of professional experience and senior rank in their discipline. This team served as the core decision-making body, appraising candidate components, adapting them to local conditions, and finalising the operational structure across two formal face-to-face meetings held in February and March 2025. Foundational inputs came from five complementary activities: a systematic review of non-pharmacological interventions, semi-structured interviews with healthcare professionals, economic and resource considerations, programme theory development, and contextual analysis. The systematic review included 21 randomised controlled trials reported in 22 publications, all conducted in China, and revealed a strikingly uneven evidence base. Evidence was most extensive for nutritional interventions, while exercise and probiotic approaches were supported by fewer, more heterogeneous studies.

The qualitative component provided the implementation intelligence that evidence alone cannot supply. Of 26 healthcare professionals invited, 21 participated in interviews conducted between January and February 2025, spanning five physicians, seven nurses, three dietitians, two physiotherapists, two clinical pharmacists, and two psychologists. Reflexive thematic analysis, informed by the Theoretical Domains Framework as a sensitising lens, generated three overarching themes comprising eleven subthemes: knowledge and competency gaps, structural and implementation barriers, and key intervention suggestions. Participants described limited recognition of sarcopenia, unclear professional responsibilities, and fragmented multidisciplinary care. For pathway development, these findings were synthesised into four cross-cutting implementation requirements: recognition and professional competency, care organisation and multidisciplinary coordination, longitudinal monitoring and continuity of care, and patient self-management and family-supported care. Each requirement was mapped directly to a design response in the final pathway, creating an auditable link between what clinicians said was missing and what the pathway delivers.

Resource realities shaped several pragmatic decisions. Routine vitamin D supplementation was not adopted; it was restricted to patients with documented deficiency, following locally approved laboratory and clinical procedures. Probiotic support was retained as a context-adaptable rather than universally fixed component, because the formulations evaluated in nasopharyngeal carcinoma trials were not fully matched by locally available products, and similar products had limited routine affordability. Repeated specialised immunological testing was judged too resource-intensive for routine longitudinal care, so the team instead selected pragmatic supplementary monitoring measures derived from routinely collected clinical parameters, including the global immune-nutrition-inflammation index, the HALP score combining hemoglobin, albumin, lymphocyte, and platelet counts, and the prognostic nutritional index. These indices were not used as standalone diagnostic thresholds; their trends were interpreted alongside body weight, oral intake, symptoms, and treatment tolerance to inform reassessment and escalation decisions.

The final pathway rests on three interconnected structural elements. First, it specifies discipline-specific roles within a coordinated multidisciplinary workflow: physicians oversee clinical assessment and medical management, nurses conduct comprehensive assessment and education while coordinating communication, dietitians adjust individualised nutritional plans, physiotherapists assess function and guide safe activity, psychologists manage distress and support behavioural adaptation, and clinical pharmacists support symptom and medication management. Second, it defines six longitudinal care procedures: assessment and individualised planning, one-to-one education, weekly monitoring, multidisciplinary consultation for complex or escalating needs, scheduled multidisciplinary reassessment at key treatment time points, and an end-of-treatment review with a care summary. Third, it organises supportive care into five strategic domains: nutritional and immune management, exercise management, head and neck symptom cluster management, gastrointestinal symptom cluster management, and psycho-behavioural support.

Two operational features deserve particular attention. The pathway embeds a risk stratification system based on the 2019 Asian Working Group for Sarcopenia criteria, using bioelectrical impedance analysis to measure appendicular skeletal muscle mass index, handgrip strength, and six-metre gait speed. Low muscle mass with preserved strength and performance is treated as a pathway-level early-warning state, while body-weight losses of 2.5 percent and 5 percent from baseline serve as pragmatic triggers for early multidisciplinary review and further escalation of support respectively. The team is careful to note these thresholds are pathway triggers, not universally validated diagnostic cut-offs. Meanwhile, the psycho-behavioural domain is grounded in the theory of planned behaviour: education, goal setting, tailored feedback, and family reinforcement are designed to strengthen patients’ attitudes, perceived social norms, and sense of behavioural control, which in turn are hypothesised to improve adherence to nutritional, exercise, and symptom-management recommendations and ultimately preserve muscle mass, strength, and function.

Patient and family voices entered the process through informal consultations with six patients undergoing or recently completing definitive treatment and six family caregivers. Most participants were initially unfamiliar with the term sarcopenia and, after explanation by nursing staff, tended to relate it to the more familiar concept of malnutrition. Their feedback centred on practical needs, particularly nutritional support, physical activity, home-based self-management, and family involvement, and informed refinements to one-to-one education and caregiver engagement. The researchers are candid about limitations: the study did not evaluate feasibility or effectiveness, the evidence base for individual components was uneven, development was situated within the Chinese healthcare context, and patient involvement was consultative rather than a formal co-development partnership. A pilot randomised controlled trial protocol has since been published to operationalise the pathway for feasibility testing. The team’s central message stands: sarcopenia prevention during cancer treatment should be conceived not as a series of isolated interventions, but as a coordinated, longitudinal, multidisciplinary process, one that treats prevention as dynamic risk management rather than episodic repair.

Subject of Research: Development of a multidisciplinary supportive care pathway for sarcopenia prevention in patients with nasopharyngeal carcinoma undergoing definitive treatment

Article Title: Developing a supportive care pathway for sarcopenia prevention in nasopharyngeal carcinoma: a context-sensitive and implementation-oriented approach

Article References: Xia, L., Chen, S., Min, J., Ma, Z., Zhang, Y., Zhang, F., Liu, S., Yan, B., & Hayashi, N. (2026). Developing a supportive care pathway for sarcopenia prevention in nasopharyngeal carcinoma: a context-sensitive and implementation-oriented approach. Supportive Care in Cancer, 34(10), Article 1058. https://doi.org/10.1007/s00520-026-11242-4

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11242-4

Keywords: sarcopenia, nasopharyngeal carcinoma, supportive care, multidisciplinary care, cancer nutrition, exercise oncology, implementation science, Medical Research Council framework, chemoradiotherapy, patient self-management, symptom management, complex interventions